Clinical trials: Cervical Adenocarcinoma
Papillary Thyroid Carcinoma
APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.
To determine the improvement in diagnosis of papillary carcinoma by detecting mutation V600E BRAF in retrospective cases with inconclusive cytologic diagnosis (categories III, IV and V of Bethesda System)
- Trial name
- NCT02323724
- Testing
- BRAF V600E mutation by pyrosequencing technique
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Corporacion Parc Tauli
Head and Neck Cancer
Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor
RATIONALE: Drugs used in chemotherapy, such as cisplatin, carboplatin, and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00079079
- Testing
- carboplatin, cisplatin, gemcitabine hydrochloride
- Where
- 4 sites in Canada
- Volunteers
- 34 people
- Sponsor
- NCIC Clinical Trials Group
Urothelial Carcinoma, Cholangiocarcinoma
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
BIND-014 (docetaxel nanoparticles for injectable suspension) is being studied in patients with advanced urothelial carcinoma, cervical cancer, cholangiocarcinoma or carcinomas of the biliary tree and squamous cell carcinoma of…
- Conditions
- Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- iNSITE2 (NCT02479178)
- Testing
- BIND-014 (docetaxel nanoparticles for injectable suspension)
- Where
- 23 sites in United States, Russia
- Volunteers
- 73 people
- Sponsor
- BIND Therapeutics
Anxiety Disorder, Depression
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
This pilot clinical trial studies stress reduction in improving quality of life in patients with recurrent gynecologic or breast cancer.
- Conditions
- Anxiety Disorder, Depression, Fatigue, Leydig Cell Tumor
- Trial name
- NCT01764789
- Testing
- questionnaire administration, quality-of-life assessment, psychosocial assessment and care
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Papillary Thyroid Carcinoma
Detection of BRAF Mutation on FNAB From Papillary Thyroid Carcinoma
Immunohistochemical detection of the BRAF-V600E mutation on pre-operative fine needle aspiration biopsy (FNAB) from patients suspected for papillary thyroid carcinoma, using the mutation specific antibody VE1.
- Trial name
- NCT02561533
- Testing
- BRAF detection on fine needle aspiration biopsy (FNAB)
- Where
- Denmark
- Volunteers
- 53 people
- Sponsor
- University of Aarhus
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
RATIONALE: Radiation therapy uses high-energy x-rays and to kill tumor cells. Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or…
- Trial name
- NCT01107639
- Testing
- cetuximab, cisplatin, docetaxel
- Where
- 57 sites in Austria, France and 3 more
- Volunteers
- 297 people
- Sponsor
- Swiss Cancer Institute
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
This randomized phase III trial is studying four combination chemotherapy regimens using cisplatin to compare how well they work in treating women with stage IVB, recurrent, or persistent cancer of the cervix.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
- Trial name
- NCT00064077
- Testing
- Cisplatin, Gemcitabine Hydrochloride, Paclitaxel
- Where
- United States
- Volunteers
- 513 people
- Sponsor
- Gynecologic Oncology Group
End of Life, Cancer
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.
- Trial name
- NCT05297734
- Testing
- Receive technology-based supportive cancer care, Receive redesigned team-based supportive cancer care
- Where
- 17 sites in United States
- Volunteers
- 2,996 people
- Sponsor
- Stanford University
Esophagus Adenocarcinoma, Esophagus Cancer
Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma
Locally advanced adenocarcinoma of the esophagus is a leading cause of death from malignant disease in Germany and has been characterized on a molecular level in recent years.
- Conditions
- Esophagus Adenocarcinoma, Esophagus Cancer, Metabolome, Mass Spectrometry
- Trial name
- NCT06642506
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
This phase II trial is studying how well aflibercept works in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine therapy.
- Conditions
- Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma
- Trial name
- NCT00729157
- Testing
- Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and irinotecan, work in different ways to stop the growth of tumor…
- Trial name
- NCT00290719
- Testing
- cisplatin, gefitinib, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Solid Tumor, Adult, Advanced Solid Tumor
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT05864144
- Testing
- SNS-101 (anti-VISTA), Cemiplimab
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sensei Biotherapeutics, Inc.
Pancreatic Cancer, Gastrointestinal Neoplasms
Permission to Collect Blood Over Time for Research
To determine whether biomarkers assessed in blood samples can be used to detect individuals at risk for developing blood clots or worsening of their underlying disease.
- Conditions
- Pancreatic Cancer, Gastrointestinal Neoplasms, Colon Rectal Cancer Adenocarcinoma, Esophageal Cancer
- Trial name
- NCT00767234
- Testing
- Observation
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Stanford University
Glioma, Hematopoietic and Lymphoid Cell Neoplasm
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction.
- Conditions
- Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT01638533
- Testing
- Pharmacological Study, Romidepsin
- Where
- 12 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Gastric Cancer
Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00020787
- Testing
- G17DT Immunogen, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Esophageal Cancer, Gastric (Stomach) Cancer
Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers
This is a single blind, case control, multicenter study jointly developed by Zhongshan Hospital of Fudan University, Shanghai Public Health Clinical Center, Shanghai Xuhui Central Hospital, Qingpu Branch of Zhongshan Hospital…
- Conditions
- Esophageal Cancer, Gastric (Stomach) Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- Trial name
- NCT05431621
- Where
- 4 sites in China
- Volunteers
- 2,430 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Follicular Thyroid Cancer, Insular Thyroid Cancer
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
This randomized phase II trial studies how well dabrafenib works with or without trametinib in treating patients with recurrent thyroid cancer.
- Conditions
- Follicular Thyroid Cancer, Insular Thyroid Cancer, Papillary Thyroid Cancer, Recurrent Thyroid Cancer
- Trial name
- NCT01723202
- Testing
- dabrafenib, trametinib
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Bhavana Konda
Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma
FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer
This phase II trial is studying how well PET scans using fluoromisonidazole F 18 and fludeoxyglucose F 18 work in finding oxygen in tumor cells of patients undergoing treatment for newly diagnosed stage 1B, stage II, stage II, or…
- Conditions
- Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer
- Trial name
- NCT00559377
- Testing
- 18F-fluoromisonidazole, fluorodeoxyglucose F 18, positron emission tomography
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.